PCVX Stock Analysis: Vaxcyte | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 10.337m USD | 12M Return: 53.2% | US92243G1085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 144M
Warnings
No concerns identified
Tailwinds
No distinct edge detected
Seasonality 6.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Vaxcyte, Inc. (PCVX) is a clinical-stage biotechnology company headquartered in San Carlos, California, that develops conjugate and novel protein vaccines targeting bacterial infectious diseases. Its pipeline is led by VAX-24, a 24-valent carrier-sparing pneumococcal conjugate vaccine (PCV) in development for preventing invasive pneumococcal disease (IPD) in infants, alongside VAX-31, a 31-valent PCV aimed at both adults and children. Additional earlier-stage candidates include VAX-A1 (Group A Streptococcus), VAX-PG (periodontitis), VAX-GI (Shigella-related dysentery), and VAX-XL, a third-generation PCV. The company was originally incorporated in 2013 as SutroVax, rebranded to Vaxcyte in May 2020, and completed its IPO on NASDAQ in June 2020.
As a clinical-stage biotech, Vaxcyte generates no commercial product revenue and is funded primarily through equity markets and development partnerships, with its valuation reflecting pipeline and clinical-milestone expectations rather than current sales. The company operates within the competitive pneumococcal vaccine space, where established products such as Pfizers Prevnar franchise and Mercks Vaxneuvance already address the IPD market, positioning Vaxcytes broader-valent candidates as potential next-generation challengers if approved.
- VAX-24 Phase 3 infant trial readout approaches
- Pfizer Prevnar 20 competition pressures pneumococcal market share
- Cash burn widens as clinical pipeline expands
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.32 > 0.02 and ΔFCF/TA -13.68 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.32 > 3% & CFO -962.0m > Net Income -1.15b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 7.66 > 1.5 & < 3 |
| Outstanding Shares: last quarter (148.9m) vs 12m ago 9.33% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%) |
| Interest Coverage Ratio: error (cannot be calculated; needs correct EBIT TTM and Interest Expense TTM) |
| A: 0.66 (Total Current Assets 2.26b - Total Current Liabilities 295.7m) / Total Assets 2.99b |
| B: -1.02 (Retained Earnings -3.06b / Total Assets 2.99b) |
| C: -0.40 (EBIT TTM -1.23b / Avg Total Assets 3.08b) |
| D: 4.98 (Book Value of Equity 2.49b / Total Liabilities 499.9m) |
| Altman-Z'' = 3.53 = A |
As of November 07, 2026, the stock is trading at USD 63.89 with a total of 1,840,628 shares traded. Over the past week, the price has changed by +3.00%, over one month by -4.21%, over three months by +8.49% and over the past year by +53.18%.
Current recommended Stop Loss: 59.50 (which is 6.9% or 1.2 ATR below the current price).
Vaxcyte has received a consensus analysts rating of 4.73. Therefore, it is recommended to buy PCVX.
- StrongBuy: 9
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 117.3 | 83.6% |
P/B = 3.4737
Revenue TTM = 0.0 USD
EBIT TTM = -1.23b USD
EBITDA TTM = -1.21b USD
Long Term Debt = 204.2m USD (estimated: total debt 221.8m - short term 17.6m)
Short Term Debt = 17.6m USD (from shortTermDebt, last quarter)
Debt = 337.3m USD (from shortLongTermDebtTotal, last quarter) + Leases 115.4m
Net Debt = -1.93b USD (calculated: Debt 337.3m - CCE 2.26b)
Enterprise Value = 8.41b USD (10.3b + Debt 337.3m - CCE 2.26b)
Interest Coverage Ratio = unknown (Ebit TTM -1.23b / Interest Expense TTM 0.0)
EV/FCF = -8.70x (Enterprise Value 8.41b / FCF TTM -966.2m)
FCF Yield = -11.49% (FCF TTM -966.2m / Enterprise Value 8.41b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = 2.81 (Enterprise Value 8.41b / Total Assets 2.99b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 337.3m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -972.6m (EBIT -1.23b * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 7.66 (Total Current Assets 2.26b / Total Current Liabilities 295.7m)
Debt / Equity = 0.14 (Debt 337.3m / totalStockholderEquity, last quarter 2.49b)
Debt / EBITDA = 1.60 (negative EBITDA) (Net Debt -1.93b / EBITDA -1.21b)
Debt / FCF = 1.99 (negative FCF - burning cash) (Net Debt -1.93b / FCF TTM -966.2m)
Total Stockholder Equity = 2.73b (last 4 quarters mean from totalStockholderEquity)
RoA = -37.28% (Net Income -1.15b / Total Assets 2.99b)
RoE = -42.04% (Net Income TTM -1.15b / Total Stockholder Equity 2.73b)
RoCE = -41.93% (EBIT -1.23b / Capital Employed (Equity 2.73b + L.T.Debt 204.2m))
RoIC = -35.88% (negative operating profit) (NOPAT -972.6m / Invested Capital 2.71b)
WACC = 9.21% (E(10.3b)/V(10.7b) * Re(9.51%) + D(337.3m)/V(10.7b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.51% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.06 | Cagr: 11.21%
[DCF] Fair Price = unknown (Cash Flow -966.2m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.61 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=-8.14 | Chg30d=+0.70% | Revisions=+0% | GrowthEPS=-44.6% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-7.12 | Chg30d=+1.36% | Revisions=+17% | GrowthEPS=+12.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: +12% (up=3, down=2)